PubRank

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Clinical Trial ID NCT01846416

PubWeight™ 31.61‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01846416

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013 4.78
2 Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014 1.35
3 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
4 Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015 1.23
5 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
6 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
7 Immune modulation for cancer therapy. Br J Cancer 2014 1.15
8 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
9 New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 2015 1.12
10 The evolving genomic classification of lung cancer. J Pathol 2014 1.08
11 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
12 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
13 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
14 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
15 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
16 New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res 2014 0.94
17 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
18 Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015 0.87
19 Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2013 0.87
20 Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol 2015 0.82
21 Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. Med Oncol 2014 0.80
22 The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget 2016 0.79
23 Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. Semin Oncol 2014 0.79
24 Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015 0.78
25 Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol 2014 0.78
26 Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. Transl Lung Cancer Res 2015 0.78
27 PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. Onco Targets Ther 2016 0.78
28 Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. Ann Transl Med 2016 0.77
29 Prime time for immune-checkpoint targeted therapy at ASCO 2015. Oncoimmunology 2015 0.75
30 Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol 2014 0.75
Next 100